
Embecta Corp (EMBC) Stock Forecast & Price Target
Embecta Corp (EMBC) Analyst Ratings
Bulls say
Embecta is facing challenges in its core market, particularly in the U.S., leading to reduced profitability and a revision of its capital allocation priorities. However, its efforts to transition into a broader medical device company and add sales growth may still take shape if the core market stabilizes. The company's revenue and earnings are expected to decline in the near term, with limited visibility for improvement. Despite these challenges, the company has a strong portfolio of products and a leading position in the market, and trades at a discount to its peers.
Bears say
Embecta is a medical device company with a diverse portfolio of products aimed at helping patients with diabetes. Despite its market leadership and global presence, the company has recently faced challenges in the US market, leading to a significant decline in its profitability outlook. This, coupled with the uncertainties surrounding future headwinds and commercial execution, has resulted in a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Embecta Corp and is not a guaranteed prediction by Public.com or investment advice.
Embecta Corp (EMBC) Analyst Forecast & Price Prediction
Start investing in Embecta Corp (EMBC)
Order type
Buy in
Order amount
Est. shares
0 shares